Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan
Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan
复制标题
DOI：
10.1128/aac.00915-19
复制
发表时间：
2019-09-01
影响因子：
4.9
通讯作者：
Cirillo, Daniela Maria
中科院分区：
文献类型：
--
作者：
Ghodousi, Arash;Rizvi, Alamdar Hussain;Cirillo, Daniela Maria
我们报告在巴基斯坦获得性耐药贝达喹啉的前六例。通过MIC检测和相关基因突变检测，对来自30例接受含贝达喹啉治疗方案的耐药结核病患者的70株连续分离株进行了贝达喹啉耐药性回顾性检测。我们记录了治疗失败的病例，这些病例在Rv0678中发生了特定突变，并且在治疗期间与氯法齐明交叉耐药相关的MIC增加。这项研究强调了新药引进后监测计划的相关性。
We report on the first six cases of acquired resistance to bedaquiline in Pakistan. Seventy sequential isolates from 30 drug-resistant-tuberculosis patients on bedaquiline-containing regimens were retrospectively tested for bedaquiline resistance by MIC testing and by the detection of mutations in relevant genes. We documented cases failing therapy that developed specific mutations in Rv0678 and had increased MICs associated with cross-resistance to clofazimine during treatment. This study underlines the relevance of surveillance programs following the introduction of new drugs.